Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs placebo added to insulin glargine ± metformin in type 2 diabetes
2019-000860-99Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Tirzepatide arm with Placebo arm (2 arms). Primary endpoint: Change in HbA1c from baseline at 40 weeks. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-000860-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000860-99.